Company Overview and News

Chinese stake in casino 'not out of the realm of possibility'

The proponents of a $3 billion casino resort on the Gold Coast have acknowledged that the Chinese Government could be a part owner.
Upvote Downvote

Piramal Fund pumps ₹1,020 cr into 2 projects via flexi lease renting scheme

2017-02-15 thehindubusinessline
Piramal Fund Management (PFM) has sanctioned two investments worth ₹1,020 crore under the flexible Lease Rental Discounting (LRD) scheme.
Upvote Downvote

PFM okays two projects of Rs 1,020 cr under flexi LRD scheme

2017-02-15 moneycontrol
Ensure that your correct email id and mobile has been registered with moneycontrol. If not, please update your profile and secure the account now. Updating your email id and mobile number offers following benefits:
Upvote Downvote

Piramal sanctions Rs 2,000 crore for office projects from flexible rental scheme

2017-02-15 livemint
Bengaluru: Piramal Finance Pvt Ltd, the non-banking financial company (NBFC) of Piramal Enterprises Ltd, has sanctioned investments of around Rs 2,000 crore from its recently launched Flexi Lease Rental Discounting (LRD) scheme for completed commercial office and retail assets, the company said on Wednesday.
Upvote Downvote

ASF Group Ltd receives full loan repayment from Rey Resources

ASF Group Ltd (ASX:AFA) is a Sino-Australia investment and trading house with a focus on the identification, incubation and realization of opportunities in areas of synergy between China and Australia.
Upvote Downvote

ASF Group Ltd consortium shortlisted for Royal Docks, Albert Island tender

ASF Group Ltd (ASX:AFA) is a Sino-Australia investment and trading house with a focus on the identification, incubation and realization of opportunities in areas of synergy between China and Australia.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

2018-04-25 - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...